Teva Pharmaceutical Industries (NYSE:TEVA) had its target price boosted by analysts at Leerink Swann from $15.00 to $17.00 in a note issued to investors on Friday. The brokerage presently has an “underperform” rating on the stock. Leerink Swann’s target price would suggest a potential downside of 20.45% from the company’s current price.
TEVA has been the topic of a number of other reports. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Friday, December 15th. Credit Suisse Group restated an “underperform” rating and set a $8.00 target price (down from $14.00) on shares of Teva Pharmaceutical Industries in a report on Monday, November 6th. Cantor Fitzgerald set a $18.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday, December 28th. Wells Fargo & Co restated a “market perform” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, October 5th. Finally, Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Sunday, November 12th. Eight research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.76.
Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.21 during mid-day trading on Friday, hitting $21.37. 1,721,671 shares of the stock were exchanged, compared to its average volume of 20,166,840. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market capitalization of $20,990.00, a price-to-earnings ratio of -3.63, a PEG ratio of 1.49 and a beta of 0.54. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $37.94.
Several large investors have recently added to or reduced their stakes in the business. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at about $106,000. Penserra Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $129,000. Fieldpoint Private Securities LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $171,000. Chevy Chase Trust Holdings Inc. grew its stake in shares of Teva Pharmaceutical Industries by 81.5% in the third quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock valued at $215,000 after acquiring an additional 5,497 shares in the last quarter. Finally, Comprehensive Portfolio Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $226,000. Hedge funds and other institutional investors own 51.89% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first reported by American Market News and is owned by of American Market News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/26/teva-pharmaceutical-industries-teva-price-target-raised-to-17-00.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
